Ekuinas makes maiden pharma investment


Ekuinas chief executive officer Syed Yasir Arafat Syed Abd Kadir (pic) said their entry into the healthcare and pharmaceutical space was timely as it looked to capitalise on global megatrends and demographic shifts amid the emergence of Covid-19.

KUALA LUMPUR: Ekuiti Nasional Bhd (Ekuinas) has made its maiden investment into the pharmaceutical industry with the acquisition of a controlling stake in Medispec (M) Sdn Bhd, based on an enterprise value of RM88.5mil.

The government-linked private equity fund management company said it was highly cognisant of the macro themes at play, which led to its entry into the industry.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Fahmi: Malaysia's economy remains strong, continues to be the focus of foreign investors
Carimin acquires 19.5% stake in Sealink International for RM40mil
TNB terminates renewable energy PPA with Reneuco
Sunway to proceed with RM11bil takeover of IJM
KIP-REIT expects higher footfall across its malls
Oxford Innotech wins RM4.8mil data centre job
Suria Capital appoints Abd Rahman Dahlan as chairman
Ringgit closes higher amid US-EU tariff concerns, easing Japanese government bonds
Shin Yang secures RM117.7mil vessel deal
UOA REIT reports threefold profit increase in 4Q25

Others Also Read